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Background: Cirrhosis patients are prescribed multiple medications for their liver disease and comorbidities.
Discrepancies between medicines consumed by patients and those documented in the medical record may
contribute to patient harm and impair disease management. The aim of the present study was to assess the
magnitude and types of discrepancies among patient-reported and medical record-documented medications in
patients with cirrhosis, and examine factors associated with such discrepancies.
Methods: Fifty patients who attended a hospital hepatology outpatient clinic were interviewed using a
questionnaire composed of mixed short-response and multiple-choice questions. Patients’ reported medication use
was compared with documentation in the hospital medical records and pharmacy database. Medication adherence
was assessed using the 8-question ©Morisky Medication Adherence Scale (MMAS-8). The multivariate logistic
regression model was constructed using clinically relevant and/or statistically significant variables as determined by
univariate analysis. All p-values were 2-sided (α = 0.05).
Results: Twenty-seven patients (54.0 %) had ≥1 discrepancy between reported and documented medicines.
Patients with ≥1 discrepancy were older (p = 0.04) and multivariate analysis identified taking ≥5 conventional
medicines or having a ‘low’ or ‘medium’ adherence ranking as independent predictors of discrepancy (adjusted OR
11.0 (95 % CI 1.8–67.4), 20.7 (95 % CI 1.3–337.7) and 49.0 (95 % CI 3.3–718.5) respectively). Concordance was highest
for liver disease medicines (71.9 %) and lowest for complementary and alternative medicines (14.5 %) and
respiratory medicines (0 %).
Conclusion: There is significant discrepancy between sources of patient medication information within the
hepatology clinic. Medication reconciliation and medicines-management intervention may address the complex
relationship between medication discrepancies, number of medications and patient adherence identified in this study.
Keywords: Medication reconciliation, Medication adherence, Liver cirrhosis, Complementary therapies, Ambulatory careBackground
Liver disease is gaining global recognition as an important
chronic health disorder, due to increasing prevalence of
non-alcoholic fatty liver disease (NAFLD), hazardous alco-
hol intake and viral hepatitis [1]. Regardless of aetiology,
morbidity and mortality occurs predominantly among pa-
tients with cirrhosis, a late stage of progressive fibrosis* Correspondence: e.powell@uq.edu.au
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cirrhosis is defined as “compensated”, a latency period
with median survival times of more than 12 years, or “de-
compensated”, a rapidly progressive phase marked by
complications of portal hypertension or liver insufficiency
and median survival times of less than 2 years [2].
The morbidity and health care costs associated with the
complications of decompensated cirrhosis are substantial,
as people require complex medical care and have very
high use of hospital services [3, 4]. With the growing
prevalence of liver cirrhosis worldwide, it is becoming
increasingly important to identify potentially-modifiable
factors that may contribute to disease burden.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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ications for therapeutic or prophylactic use [3] and the
number of medications prescribed on hospital dis-
charge is a risk factor for early readmission [5]. Al-
though the precise reason for this has not been
established, and increased medication use is common
in people with more severe illness, medication misuse
and non-adherence may have contributed. Polyphar-
macy is strongly related to poor adherence and both
factors have also been associated with medication mis-
use and a higher prevalence of discrepancies between
patient-reported and clinician-documented medications
[6, 7]. Discrepancies between the type and frequency of
medications prescribed by clinicians and the drugs
actually consumed by patients may contribute to pa-
tient harm or reduce the efficacy of therapy. Unresolved
medication discrepancies have been correlated with in-
creased length of hospital stay, readmission within
30 days and adverse events post-discharge [8–10].
In contrast to other chronic diseases, the prevalence of
medication discrepancies has not been examined in pa-
tients with cirrhosis. Examination of the types and mag-
nitude of discrepancies that are present and the
potential harms associated with them is important to
improve clinician recognition of this potential barrier to
care, especially with the growing push for treatment and
follow-up of chronic liver disease (CLD) patients in
community settings.
Aims
To assess the magnitude and types of discrepancies be-
tween reported and documented medications in patients
with cirrhosis seen in a hospital hepatology clinic, and
examine factors associated with such discrepancies.
Methods
Patients and clinical data
A convenience sample of 50 English-speaking patients
with cirrhosis were invited to participate when they
attended the hepatology outpatient clinic at the Princess
Alexandra Hospital (Brisbane, Australia) from August to
December 2014.
Participants (and carers/family members if present)
were interviewed by the research co-ordinator using a
questionnaire composed of mixed short-response and
multiple-choice questions designed to elicit demographic
information, patient knowledge of their medications and
liver disease and related lifestyle factors. Self-reported
adherence to cirrhosis medications was evaluated using
the eight-item Morisky Medication Adherence Scale©
(MMAS-8) with approval from the developer [11–13].
The MMAS-8 is a previously validated questionnaire
used to estimate self-reported adherence to treatment
and is widely used in chronic diseases. It consists ofseven questions with “yes” or “no” alternatives, and one
item featuring a 5-point Likert scale. The MMAS-8
scores range from 0–8, with levels of adherence classi-
fied as: high adherence (score 8); medium adherence
(score 6–7.75); and low adherence (score <6).
Patients’ medical records, standard biochemical and
serological assays and liver imaging were used to con-
firm the diagnosis of liver disease and cirrhosis. In
addition, Fibroscan®, gastroscopy and histological assess-
ment of a liver biopsy were also used, if performed. The
severity of liver disease was evaluated using the Child-
Turcotte-Pugh classification.
Patient reported medications
Subjects were asked to list the dose, frequency and in-
dication for each of their medicines and specifically
prompted for over-the-counter (OTC) and comple-
mentary medicines (CAMs). Qualitative questions were
also asked throughout the interview to elicit individual
medication-taking behaviour. Medications were not ac-
tively verified with other sources such as the GP or
local pharmacy, as medication reconciliation was not
standard practice within the clinic at the time this study
was conducted.
Documented medications
Medications were considered current if documented less
than 3 months prior to patient interview, without subse-
quent documentation of cessation or modification. Each
patient’s medical record and the pharmacy database
‘ELMs’ (Enterprise-wide Liaison Medication System)
were interrogated to determine documented medications
and compare to patient responses. ELMs is a state-wide
hospital pharmacy database that is routinely updated by
hospital pharmacists at the point of admission and/or
discharge from hospital. Within the outpatient hepatology
clinic there was no assigned clinician or assistant who
routinely verified and updated the patient’s medication list.
Consequently, medications were not consistently recorded
within the outpatient section of the medical record, and
thus correspondence letters from GPs, other specialists
and admission notes were also used to determine docu-
mented medications.
Data analysis
‘Medication discrepancy’ was defined as a difference be-
tween what was reported by the patient and what was
documented in the medical record or in ELMs. Docu-
mented medications in the ELMs database which were
annotated or classified as ‘temporary’ by the study clini-
cians (antibiotic courses, post-operative analgesia, some
PRN medications, medicines with a documented cessa-
tion date) were not included in the discrepancy analysis.
Fig. 1 Number of discrepancies between patient-reported conventional
medications (including prescribed CAMs) and their medical record
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name, dose, frequency and indication was attempted, but
due to patient ambiguity and limited chart documentation
of dosage, only the name of medications could be analysed
for this study. The clinical significance of discrepancies was
determined by a panel of clinicians experienced in treating
cirrhosis patients (pharmacist, hepatologist and nurse). A
significant discrepancy was defined as one which may lead
to potential harm within 7 days if the patient was adminis-
tered, or not administered, a drug due to misdocumenta-
tion or misreporting. Medications which were in agreement
between 2 sources were considered ‘concordant’.
Medications were categorised as ‘conventional medica-
tions’ (including prescription medicines, OTCs, vitamins and
protein supplements prescribed for the treatment of
cirrhosis-related complications and other comorbidities) or
‘CAMs’. Medications were grouped into 12 drug-disease cat-
egories: liver, gastrointestinal-luminal, cardiovascular, dia-
betes, psychomodulators, analgesia, CAMs, respiratory and
‘others’. Proton-pump inhibitors (PPIs) were classified as a
‘liver’ medication in patients with gastric and/or oesophageal
varices or a ‘gastro-luminal’ medication when prescribed for
gastro-oesophageal reflux disease. Liver disease medications
were further analysed by drug name and/or indication.
Statistical analysis
Data analysis was conducted using SPSS Inc. version 20.0
(College Station TX: StatCorp LP; 2013). Participant char-
acteristics are presented as means and standard deviation
(normally distributed data), and proportions. Univariate
analysis was performed using Pearson’s Chi-squared ana-
lysis or Fisher’s Exact test for categorical data (propor-
tions), and t-test for normally-distributed data (means).
The association between medication discrepancy and
demographic and clinical variables was determined by cal-
culating the odds ratios (OR) and 95 % confidence interval
(CI). The multivariate logistic regression analysis model
was constructed by testing variables of clinical relevance
and/or statistical significance as determined by univariate
analysis. The Hosmer-Lemeshow test was performed on
selected models to assess goodness-of-fit. The final model
was used to assess associations after adjustment for the
total number of conventional medications taken by pa-
tients (excluding CAMs), and MMAS ranking. Interac-
tions between individual variables (age, gender, regular
general practitioner (GP), comorbidities, number of con-
ventional medications and MMAS ranking) were not
found to be statistically significant. All p values were 2-
sided and statistical significance was set at alpha = 0.05.
Results
Patient characteristics
Fifty-three cirrhotic patients who attended the hepa-
tology clinic at the Princess Alexandra Hospital wereinvited to participate; 50 (94.0 %) were interviewed, and
three declined to participate. Overall, the mean age of
participants was 58.5 (±10.2) years; 39 patients (78.0 %)
were men and 43 (86.0 %) were Caucasian. Primary liver
disease aetiology was Hepatitis C in 26 patients; non-
alcoholic steatohepatitis in 11; alcoholic liver disease in
10; Hepatitis B in one; primary biliary cirrhosis in one;
cryptogenic in one. Twenty patients (40.0 %) had de-
compensated cirrhosis at the time of interview, including
five with a history of hepatic encephalopathy, 14 with
ascites and 15 with oesophageal/gastric varices.
A total of 307 medications were identified from all
sources; 244 were classified as ‘conventional’, 63 as
CAMs, and the drug-disease classes comprised liver-
related (22.8 %), CAM (20.5 %), cardiovascular (15.6 %),
diabetes (8.8 %), “other” (8.5 %), psychomodulators
(8.1 %), analgesia (7.2 %), gastro-luminal (4.9 %) and re-
spiratory (3.6 %) medications. Seven patients (14.0 %)
stated that they took no medications, however two
disclosed OTC/CAMs when prompted and one had
salbutamol ‘when required’ documented within their
medical record. Twenty-seven patients (54.0 %) had ≥5
conventional medications identified from all sources.
Medication discrepancies
Significant discrepancies between patient-reported con-
ventional medications (including prescribed CAMs) and
the medical record were present in 27 patients (54.0 %).
All 27 patients reported conventional medications which
were not recorded in the medical record and 16 patients
also did not report conventional medications that were
documented in the medical record. Twenty-four percent
of patients had three or more discrepancies among
conventional medicines identified (Fig. 1).
Sixteen patients had medications recorded in the
ELMs database. Of these 16 patients, discrepancies in
conventional medicines were present in 11 patients
(68.8 %); five reported conventional medications which
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recorded in ELMs which they did not report.
Figure 2 describes the overall concordance and dis-
cordance between medications reported by patients and
documented in their medical records and the ELMs
database. A total of 246 medications (including CAMs)
were reported by the cohort of 50 patients and 160 were
documented in their medical records. Overall, 125 of
281 medications (44.5 %) were concordant between the
patient and their medical record. Twenty-six medica-
tions documented in ELMs were not reported by pa-
tients or documented in their medical record; these
included records of insulin, liver, cardiovascular and
respiratory medicines. A large proportion of patient-
reported medications that were not documented in the
medical record were CAMs.
The distribution of medication discrepancies by drug-
disease class between patients and their medical records,
and between the medical record and ELMs is presented
in Fig. 3a and 3b respectively. Discrepancies in me-
dications prescribed for the management of liver disease
and cirrhosis-related complications are summarised in
Table 1. Propranolol and anti-viral therapies were 100 %
concordant between the patient and the medical record.
Only two of the five patients who were recorded as tak-
ing lactulose for hepatic encephalopathy reported using
it. The one patient who reported taking trimethoprim-
sulfamethoxazole for spontaneous bacterial peritonitis
(SBP) prophylaxis did not have this medication docu-
mented within their medical record.
Qualitative analysis of medication discrepancies iden-
tified three patients using benzodiazepines and five
patients who were taking opiates or non-steroidal anti-
inflammatory analgesics not documented in their medical
record. One patient took moclobemide, a monoamine-
oxidase inhibitor (MAOI) which was not documented,
and two patients had angiotensin II receptor antagonists
documented in the chart, but not reported by the patient.
Five patients had discrepancies involving insulin. OnlyFig. 2 Venn distribution of medications reported by patients, documented
medications that were concordant between sources. Total number of medtwo of the six patients with documented inhalers reported
using them.
Factors associated with medication discrepancy
The demographic and clinical characteristics of patients
according to the presence or absence of medication dis-
crepancies between the patient and medical record is
summarised in Table 2. Patients with ≥1 medication
discrepancy were older (p = 0.04), more likely to be tak-
ing ≥5 conventional medications (p = 0.01), had a regu-
lar GP (p = 0.04), comorbidities (p = 0.02) and a lower
adherence ranking (p < 0.01). Multivariate analysis iden-
tified the total number of conventional medications and
the MMAS ranking as the most significant predictors
of discrepancy (Table 3). Patients taking ≥5 conven-
tional medications were 11.0 (95 % CI 1.8–67.4) times
more likely to have at least one discrepancy; those with
a ‘low’ or ‘medium’ adherence ranking were 20.7 (95 %
CI 1.3–337.7) and 49.0 (95 % CI 3.3–718.5) times more
likely to have at least one medication discrepancy com-
pared to those with a ‘high’ MMAS ranking.
Of the 20 participants who had decompensated cir-
rhosis, five had a history of hepatic encephalopathy. En-
cephalopathy was not associated with medication
discrepancies in the whole group (n = 50, p = 0.36), nor
in the subset of decompensated patients (n = 20, p =
0.60) although this finding may be limited by sample
size.
Over-the-counter (OTC), complementary and alternative
medications (CAMs)
When initially asked to list their medications, only
31.8 % of over-the-counter, complementary and al-
ternative medications were volunteered by patients.
Further specific questioning about OTC products and
CAMs were required to elicit these medicines. In
total, twenty-seven patients reported taking CAMs,
including two patients who stated that they took no
medications at all. Only 14.5 % of CAMs reported byin their medical records and recorded in ELMs. Overlap represents
ications = 307 (n = 63 CAMS; n = 244 conventional medicines)
ab
Fig. 3 a. Concordance between medications reported by the patient and documented in their medical record with respect to drug-disease
category. Patients (n = 50) taking ≥1 medication in drug-disease class: liver n = 28; CAMs n = 28; cardiovascular n = 22; diabetes n = 14;
psychomodulators n = 13; analgesia n = 17; other n = 14; gastro-luminal n = 10; respiratory n = 5. b. Concordance between medications
recorded in ELMs and documented in the medical record with respect to drug-disease category. Patients (n = 16) taking ≥1 medication in
drug-disease class: liver n = 11; CAMs n = 10; cardiovascular n = 7; diabetes n = 5; psychomodulators n = 3; analgesia n = 5; other n = 5;
gastro-luminal n = 5; respiratory n = 4
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whereas ELMs had a 60.0 % concordance rate within
the group of 16 patients who had records in this
database.Barriers to knowledge and adherence
Of the 43 patients who reported taking medications,
only 24 patients (56.0 %) recalled being told how to take
them. Eighty-five percent of decompensated patients




Patient reported but not
documented in medical record
Documented in medical record
but not reported by patient
Concordant medications Proportion (%) discordant records
within drug-disease category
Diuretics n = 16 1 2 13 18.8 %
Propranolol n = 9 0 0 9 0.0 %
Cholecalciferol n = 8 4 0 4 50.0 %
PPIs n = 7 2 1 4 42.9 %
Thiamine n = 6 1 0 5 16.7 %
Lactulose n = 5 0 3 2 60.0 %
Antivirals n = 4 0 0 4 0.0 %
Other n = 9b 3 1 5 44.4 %
aExcluding 6 liver medications which were only documented in ELMs (n = 1 for thiamine, rifaximin, PPI, lactulose, cholecalciferol, spironolactone)
bRifaximin, spontaneous bacterial peritonitis prophylaxis, ursodeoxecholic acid, other vitamins and protein supplements prescribed for complications of cirrhosis
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to 40 % of compensated cirrhotics (p < 0.01), which is
consistent with disease management of ascites. Decom-
pensated patients were also more likely to be taking di-
uretics (p < 0.01), but less than one-third knew to keep a
record of weight and blood pressure which can both be
variably affected by disease and pharmacotherapy.
Fourteen patients (33.0 %) stated that they could not





Years attending clinic, median (range)
Liver disease severity Compensated
Decompensated
Patient has a regular GP
Comorbidities presenta
Level of Education Primary/High School
Higher Educationb
Currently employed
Patient reported being ‘told how to take your medications’c
Patient reported being able to afford medicationsc
No. of conventional medicinesc 1-4
≥5
Adherence ranking (MMAS-8)d High
Medium
Low
aComorbidities included cardiovascular disease, hypertension, diabetes, gastro-oeso
osteoporosis, rheumatoid arthritis, depression, anxiety, schizophrenia, asthma, chron
bTrade, technical certificate, diploma
cExcluding 4 patients who took no medications, 2 patients who only took CAMs an
significant discrepancy n = 27; no significant discrepancy n = 16). Conventional med
management of cirrhosis or other medical conditions (including: vitamin B1, vitamin
for 2 patients with symptomatic hypomagnesemia due to diuretic use, and calcium
dExcluding 10 patients who did not complete this section of the questionnaire (totabe related to employment status, polypharmacy or dis-
ease severity (p > 0.05). Of the 40 patients who com-
pleted the adherence tool, only 7 were categorised as
having ‘high’ adherence.
Discussion
In this sample of patients with cirrhosis, over half had at
least one discrepancy between their reported medicines






61 ± 8 55 ± 11 0.04
20 (74.1 %) 19 (82.6 %) 0.52






96.3 % 73.9 % 0.04
85.2 % 52.2 % 0.02
66.7 % 73.9 % 0.58
33.3 % 26.1 %
25.9 % 43.5 % 0.19
59.3 % 50.0 % 0.56













phageal reflux disease, hypothyroidism, benign prostatic hyperplasia,
ic obstructive pulmonary disease, and neuropathic pain
d 1 patient who did not answer the question (total n = 43 patients; ≥1
icines included vitamins and protein supplements prescribed for the
D, vitamin A, ferrous sulphate in 1 patient with chronic anaemia, magnesium
in 1 patient with osteoporosis)
l n = 40; ≥1 medication discrepancy n = 24; No medication discrepancy n = 16)
Table 3 Crude and multivariate predictors of medication discrepancies
Crude OR (95 % CI) Adjusted ORa (95 % CI)
Age ≥60 1.5 (0.5 – 4.7) 0.9 (0.2 – 4.7)
Male gender 0.6 (0.2 – 2.4) 1.0 (0.1 – 6.6)
Regular GP 9.2 (1.0 – 83.1) -
≥1 Comorbidity 5.3 (1.4 – 20.1) 2.8 (0.3 – 23.9)
≥5 Conventional Medicines 5.8 (1.5 – 22.7) 11.0 (1.8 – 67.4)
MMAS ranking Low 7.2 (0.6 – 81.5) 20.7 (1.3 – 337.7)
Medium 20.4 (2.00 – 211.89) 49.0 (3.3 – 718.5)
aOdds ratio adjusted for number of conventional medicines and the MMAS score. Analysis excludes 10 patients who did not complete the MMAS section of
the questionnaire
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was under 50 %. Those patients with a discrepancy were
more likely to be taking ≥5 medicines and have a
medium to low medication adherence ranking.
Discrepancies among CAMs were not unexpected as
miscommunication between patients and prescribers on
this subject is known to be extensive [14]. However, much
like conventional medicines, CAMs are not without poten-
tial harm. Adverse reactions are not uncommon [15], and a
number of herbal remedies and dietary supplements have
been linked to drug-induced liver injury, including trad-
itional Chinese medicines (xiao-chai-hu-tang, rheum pal-
matum (rhubarb), shou-wu pian), green tea extract, greater
celandine, and chaparral [16, 17]. A number of these CAMs
are purported to have benefits for patients with pre-existing
liver disease, therefore cirrhosis patients who are dissatisfied
with conventional medicine may seek out these agents.
Hepatologists should be aware of this and actively ask
patients about their alternative medication use.
A number of discrepancies among conventional medi-
cations had potential for patient harm, such as the mis-
documentation or misreporting of insulin, analgesics,
benzodiazepines and a MAOI. Errors involving insulin
can lead to hospitalisation, MAOIs have potential for
severe drug-drug interactions, opioids have reduced
clearance in cirrhosis and increased risk of constipation
and hepatic encephalopathy, and NSAIDs may contrib-
ute to renal impairment and hepatorenal syndrome.
Discrepancies involving SBP prophylaxis, diuretics and
lactulose among patients with decompensated cirrhosis
are also cause for concern, as failure to appropriately
manage or monitor these medicines may contribute to
hospitalisation with life-threatening decompensation
events.
Patients with decompensated cirrhosis average two to
three hospital admissions per year [3, 5, 18]. Upon hos-
pitalisation many patients are too unwell to discuss their
current medications and may therefore be administered
a regimen according to the documented list, which con-
tains discrepancies. Unresolved medication discrepancies
have been linked to prolonged hospital stay in peoplewith other chronic diseases [8]. With recurrent hospital-
isation, additional pharmacotherapy is often prescribed
to manage complications of cirrhosis [3]. With an in-
crease in pharmacotherapy there is a greater chance for
patient-clinician miscommunication about medications
and thus patients prescribed complex and frequently
changing medication regimens are often reported to
have poorer adherence [19]. These factors may be fur-
ther compounded by varying degrees of encephalopathy
in people with advanced cirrhosis; only 7 participants in
the present study were ranked as having ‘high’ levels of
adherence, which is lower than other chronic diseases
[12, 20, 21]. Increasing polypharmacy, intentional and
unintentional non-adherence, and discrepancies that
arise from patient-clinician miscommunication may con-
tribute to re-hospitalisation.
Among decompensated cirrhotics, the number of
medications prescribed at discharge has been found to
predict hospitalization rate and time to first hospital re-
admission, independently of the Model for End-stage
Liver Disease (MELD) score and serum sodium which
also predict poor outcomes [5]. Volk and colleagues esti-
mated that 22 % of 30-day readmissions among patients
with decompensated cirrhosis were possibly preventable
with improved patient understanding of their medica-
tions or more frequent outpatient monitoring [5]. Im-
proved patient understanding may partially be achieved
by simplification of the prescribed regimen, which may
further improve reporting and adherence due to ease of
memory, reduction in side effects and general patient
satisfaction [22–24]. However this is difficult to achieve
without knowledge of the patient’s entire medication
regimen. Routine medication reconciliation within the
hepatology clinic may improve this.
In existing outpatient models of collaborative prac-
tice, pharmacists have a designated role in medication
education and reconciliation, with a number of studies
concluding pharmacist intervention reduced hospital
admissions, increased adherence to therapy and im-
proved patient outcomes [25–27]. Enhancing the level
of disease education in patients of a low educational
Hayward et al. BMC Gastroenterology  (2016) 16:114 Page 8 of 9background has been shown to improve medication
adherence [28–31], and use of multiple sources to
construct an accurate medication record and identify
medication-related problems reduces patient harm
[32, 33]. Implementation of a pharmacist within this
hepatology practice whose role is to focus on medica-
tion reconciliation and management may improve pa-
tient outcomes.Strengths and limitations
The use of face-to-face interviews conducted by a
data collector who had experience with chronic liver
disease and was familiar with the patient group
allowed for directed qualitative expansion of some
patient responses. In addition, a pharmacist con-
ducted the ELMs reviews, assisted with the construc-
tion of medication-related questions and discrepancy
analysis. Whilst interviewer administration accommo-
dated for potential literacy problems, all patients who
completed this survey spoke and read English. There-
fore cirrhotic patients requiring an interpreter during
the consultation were excluded from assessment. Fur-
thermore, the study relied heavily on patient recall as
most patients did not bring their medicines or a list
of them to clinic. Some patients with cirrhosis have a
carer or family member who assists with managing
their medications; this person was not always present
at the time of the interview. Decompensated patients
may also have had low-grade encephalopathy, affect-
ing medication recall. However these factors reflect
the clinic scenario existing in reality, which is what
this study aimed to investigate.Conclusion
This study demonstrates that there is significant
discrepancy between medication sources within the
hepatology clinic with potential for harm or impaired
disease management. While the aforementioned limi-
tations and single-centre nature of the study may im-
pact on applicability of findings to other sites, we
have identified an important potential barrier to care,
which may present in similar general hepatology
models of care globally. There is much room for im-
provement in medication reconciliation within the
clinic, and our patients may benefit from targeted
medication-management intervention.
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